How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    Evidence generation plan for HTE10063 Digital technologies to support asthma self-management

    Open for comments Open until   Request commenting lead permission

    We have updated this service so that members of the same organisation can now collaborate on a joint online response.

    Read our blog to learn more.

    1 Purpose of this document

    NICE's early value assessment of digital technologies to support asthma self-management recommends that Asthmahub, Asthmahub for parents, AsthmaTuner, BreatheSmart/Respi.me (RDMP), Digital Health Passport, Luscii, myAsthma and Smart Asthma can be used in the NHS during the evidence generation period.

    This plan outlines the evidence gaps and what data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. Evidence generated through other study approaches will also be considered. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence.

    The companies are responsible for ensuring that data collection and analysis takes place.

    Guidance on commissioning and procurement of the technologies will be provided by NHS, which is developing a digital health technology policy framework to further outline commissioning pathways.

    NICE will withdraw the guidance if the companies do not meet the conditions in section 4 on monitoring.

    After the end of the evidence generation period (3 years), the companies should submit the evidence to NICE in a format that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS.